Renaissance Capital logo

Imago BioSciences Priced, Nasdaq: IMGO

Phase 2 biotech developing small molecules for bone marrow cancer and diseases.

Industry: Health Care

Latest Trade: $36.01 0.00 (0.0%)

First Day Return: +1.8%

Return from IPO: +125.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. We are focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives. Our lead product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. The three most common MPNs are myelofibrosis, or MF, essential thrombocythemia, or ET, and polycythemia vera, or PV. We are currently enrolling patients in a Phase 2 clinical trial of bomedemstat for the treatment of ET and have completed enrollment for a Phase 2 clinical trial of bomedemstat for the treatment of MF. In our Phase 2 clinical trial in ET through May 18, 2021, interim and unaudited data from 28 patients demonstrates that a significant proportion of patients achieved a platelet count in the normal range within eight weeks. In our Phase 2 clinical trial in MF through May 17, 2021, interim and unaudited data from 86 patients demonstrates that bomedemstat has resulted in improvements in patient symptoms, reductions in spleen volume and reduction in mutant allele frequency, or MAF, the proportion of blood cells with mutations that drive this disease. We believe bomedemstat has the potential to address unmet medical need in MF as a monotherapy as well as in combination with inhibitors of Janus-associated kinase.
more less
IPO Data
IPO File Date 06/25/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 8.4
Deal Size ($mm) $134
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/15/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 8.4
Deal Size ($mm) $134
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
TD Cowen
more
Company Data
Headquarters South San Francisco, CA, United States
Founded 2012
Employees 17
Website imagobio.com

Imago BioSciences (IMGO) Performance